Bausch HealthBHC +1.89%58 EBIT per Share is $1.95 as of Mar. 2026. GuruFocus rates BHC with a GF Score™ of 58/100 and a GF Value™ of $7.78 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 808 Drug Manufacturers companies, Bausch Health ranks better than 61.51% on this metric.
Bausch Health's EBIT per Share for the
three
months ended in Mar. 2026 was $-2.55.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.95.
During the past 12 months, the average EBIT per Share Growth Rate of Bausch Health was 28.00% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 15.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 10.90% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 6.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Bausch Health's EBIT per Share or its related term are showing as below:
BHC'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -69.6 Med: 15.5 Max: 260.7
Current: 15.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Bausch Health was 260.70% per year. The lowest was -69.60% per year. And the median was 15.50% per year.
BHC's 3-Year EBIT Growth Rate is ranked better than 61.51% of 808
companies
in the Drug Manufacturers industry
Industry Median: 7.65
vs BHC: 15.50
Bausch Health's EBIT for the
three
months ended in Mar. 2026 was $-952 Mil.
Bausch Health (NYSE:BHC) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Bausch Health EBIT per Share Related Terms
Bausch Health EBIT per Share Historical Data
* Premium members only.
The historical data trend for Bausch Health's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.95
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bausch Health (BHC) has a EBIT per Share of $1.95 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bausch Health and its competitors. According to the industry distribution chart, Bausch Health ranks #311 out of 808 companies in the Drug Manufacturers industry, placing it in the top 38.5%.
Is Bausch Health's EBIT per Share too high?
Bausch Health's current EBIT per Share is $1.95. The Drug Manufacturers industry median EBIT per Share is 7.65. Bausch Health's value of $1.95 is 74.5% below this industry median. Based on the distribution chart, Bausch Health ranks #311 out of 808 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bausch Health has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bausch Health's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bausch Health ranks #311 out of 808 companies for EBIT per Share. This puts Bausch Health in the upper half of its industry. The industry median EBIT per Share is 7.65. Bausch Health's value of $1.95 is 74.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bausch Health's current EBIT per Share of $1.95 is 74.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Bausch Health and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bausch Health's current EBIT per Share is $1.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bausch Health stock overvalued right now?
Based on GuruFocus' analysis, Bausch Health (BHC) is currently considered Possible Value Trap. The stock's GF Value™ is $7.78, compared to a current price of $4.85 — trading 37.7% below its estimated fair value. The current EBIT per Share is $1.95 and 74.5% below the Drug Manufacturers industry median of 7.65. Bausch Health's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Bausch Health (BHC), the current EBIT per Share is $1.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bausch Health (BHC) Overvalued in 2026?
Based on GuruFocus' analysis, Bausch Health stock appears to be undervalued.
The current stock price of $4.85 is trading 37.7% below its estimated GF Value™ of $7.78.
GuruFocus considers Bausch Health to be Possible Value Trap.
Key valuation signals for BHC:
EBIT per Share: $1.95
GF Value™: $7.78 vs. price of $4.85 (37.7% below fair value)
Industry Position: 74.5% below the Drug Manufacturers median (#311 of 808)
No single metric tells the full story. See the BHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
58GF Score
Get the complete analysis for BHC
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BHC has been successfully added to your 
